Injectable hormonal contraceptive does not raise HIV risk, large trial finds

Image from the live stream of Helen Rees presenting at the conference.

A large trial has found no difference in the risk of acquiring HIV for women using three different types of long-acting, reversible contraception in sub-Saharan Africa.

Findings from the ECHO study were published today in The Lancet and presented at the South African AIDS Conference in Durban.

“Our randomised trial did not find a substantial difference in HIV risk among the contraceptive methods evaluated, and all methods were safe and highly effective at preventing pregnancy,” said study co-author Professor Jared Baeten, University of Washington, USA.

The Evidence for Contraceptive Options and HIV Outcomes (ECHO) study was designed to investigate whether the long-acting contraceptive injection DMPA-IM (intramuscular depot medroxyprogesterone acetate, or Depo Provera) raised the risk of HIV infection for women compared to other widely available and highly effective methods of long-acting contraception.

Several meta-analyses of observational studies have indicated that women using DMPA-IM had a 40 to 50% higher risk of HIV infection. In 2017, the World Health Organization (WHO) recommended that women choosing an injectable progestin-only contraceptive and at high risk of HIV infection should be advised of the potential increased risk. But the expert panel that framed this guidance also concluded that more high-quality evidence was needed before WHO could issue guidelines on contraceptive choices for women at risk of HIV infection.

DMPA-IM has been used more frequently than other methods in sub-Saharan Africa, although the overall use of modern contraceptive methods remains low owing to lack of funding of contraceptive services in many countries in the region. Approximately 58 million women use modern contraceptive methods in sub-Saharan Africa.

“We have a massive unmet need for contraception in our region and the method that the majority of women are choosing or being given is injectable,” Professor Helen Rees of Wits Reproductive Health and HIV Institute, South Africa told the South African AIDS Conference.

The ECHO study compared three long-acting, reversible contraceptive methods in 7829 HIV-negative women aged 16-35 years seeking an effective contraception method in eSwatini (Swaziland), Kenya, South Africa and Zambia. Participants were recruited in districts where local epidemiology showed that women were at high risk of HIV infection.

Women were randomised to DMPA-IM, copper intrauterine device (IUD) or levenorgestrel (LNG) implant. The study was open-label as there was no way of blinding investigators or participants to the type of contraception being used.

Participants attended the trial site clinic one month after the initial visit at which the contraceptive option was first given or implanted, to check for adverse reactions, and every three months thereafter, during a follow-up period of 18 months. Participants were tested for HIV at every clinic visit and received treatment for symptomatic sexually transmitted infections. They also received HIV prevention counselling and condoms and, where available as part of national guidelines, pre-exposure prophylaxis (PrEP).

The primary outcome measured in the study was HIV infection, and the study was designed to detect a 50% increase in the risk of HIV infection for any contraceptive type.

The modified intention-to-treat analysis included all women who entered the study and tested HIV-negative at baseline and underwent an HIV test during the follow-up period (7715 women). Study retention was high: 91% of participants attended every scheduled clinic visit. Participants used their assigned contraceptive method for 92% of the time during the study.

The median age of study participants was 23 years, 81% of women were unmarried and 29% were living with a partner. Eighty-one per cent had been pregnant at least once. At baseline, just under half (48%) reported that a condom had not been used at last sexual act and 73% reported unprotected sex in the past three months. 

There were 397 HIV infections (an incidence of 3.8% per year) in the study – 143 in the DMPA-IM group (4.2% per year), 138 in the copper IUD group 3.9%), and 116 in the LNG implant group (3.3%). There was no significant difference in the risk of HIV infection according to the form of contraception used, and the lack of difference persisted when analysis was restricted to continuous users of the assigned contraceptive method (86% of the total follow-up recorded).

"This evidence will enhance women’s contraceptive decision making and assist providers and policymakers in delivering high-quality, rights-based contraceptive care.” Helen Rees

Adverse events were uncommon. Less than 4% of participants in any group reported any serious adverse event (2%, 49 women in the DMPA-IM group; 4%, 92 women in the copper IUD group; and 3%, 78 women in the LNG implant group) and less than 9% reported adverse events that led to discontinuation of the assigned contraceptive method (4%, 109 women in the DMPA-IM group; 8%, 218 women in the copper IUD group; and 9%, 226 women in the LNG implant group).

All three contraceptive methods were highly effective. Approximately 1% of women in each study arm became pregnant, among study participants who were counted as continuous users. Women using either one of the hormonal methods continuously were significantly less likely to become pregnant than women using the copper IUD method (p = 0.027).

Professor Jared Baeten warned that the results of the study cannot be extrapolated to other methods of hormonal contraception.

Helen Rees added: “These results underscore the importance of continued and increased access to these three contraceptive methods, as well as expanded contraceptive choices, complemented by high-quality HIV and STI prevention services. Women’s informed choice in sexual and reproductive health services is essential. This evidence will enhance women’s contraceptive decision making and assist providers and policymakers in delivering high-quality, rights-based contraceptive care.”

At the South African AIDS Conference, many speakers and delegates expressed concern over the high HIV incidence in study participants despite HIV prevention counselling and condom provision at study visits. Although PrEP became available at some study sites during the late stages of the trial, less than 2% of total follow-up was contributed by participants who were taking PrEP.

Yvette Raphael, a member of the ECHO Global Community Advisory Group said: “For us as women, these results are not good news. ECHO is a wake-up call for HIV prevention at every family planning clinic.”

She also criticised the tendency of family planning programmes to prioritise provision of DMPA-IM. “DMPA-IM should not continue to dominate contraception choices for women in sub-Saharan Africa,” she told the South African AIDS Conference.

References

Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. The Lancet, online ahead of print, 2019. (Full text freely available).

Related topics